WELCOME To the
ASA-NJ chapter events
ASA New Jersey Chapter and Oncology Estimand Working Group of ASA BIOP & PSI/EFSPI joint Webinar, Dec. 02, 2022 (SLIDES)
Recording of the webinar is HERE. Please click links below for the slides.
- Combining the target trial and estimand frameworks to define the causal estimand:
an application using real-world data to contextualize a single-arm trial
by Jufen Chu (Novartis)
- Benefits of target trial and estimand frameworks in real-world evidence of treatment
effects for supporting health technology assessment
by Stephen Duffield (NICE)
- Introduction to the ICH E9(R1) estimand and target trial emulation frameworks, and
their role in the design and analysis of RWE studies
by Xabier Garcia de Albeniz Martinez (RTI Health Solutions) & Lisa Hampson (Novartis)
- External control arms in oncology: current use and future directions?
by Pallavi Mishra-Kalyani (FDA)
- Applying the Estimand and Target Trial frameworks to external control analyses using
observational data: a case study in the solid tumor setting
by Letizia Polito (Roche)
ASA New Jersey Chapter and Bayer Statistics and Data Insights 9th joint Annual Workshop, Oct. 07, 2022 (SLIDES)
Please click HERE for the slides of the following
presentations.
Prof. Ciprian Crainiceanu, John Hopkins University
Presentation Title: “Wearable devices and self-reported Patient Reported Outcomes (PROs) via mobile apps with applications to observational and clinical trials”
Dr. Bohdana Ratitch, Bayer
Presentation Title: “Considerations for Analyses Contributing to Clinical Validation of Digital Health Technologies”
Dr. CV Damaraju, J&J
Presentation Title: “Digital Health Technologies in Clinical Trials: Some Recent Applications and the Regulatory Guidance”
Prof. Natallia Katenka, University of Rhode Island
Presentation Title: “Causal Inference in Networks with Applications in Public Health”
ASA New Jersey/Princeton-Trenton Chapters Joint Symposium held on June 24, 2022 (SLIDES)
- Dose optimization in oncology drug development: Where we are and how we got here by Elizabeth Garrett-Mayer, Vice President,
Center for Research and Analytics, American Society of Clinical Oncology
- Pragmatic and Holistic Approach for Dose Finding and Optimization in Oncology Drug Development – A Clinical Pharmacology Point of View by
Jiang Liu, Associate Director, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, FDA
- A Practical and Holistic approach for Dose Selection in Cancer Drug Development by
Satrajit Roychoudhury, Senior Director, Statistical Research and Data Science Center, Pfizer
- On the efficiency of the hybrid testing-modeling approach for binary responses by
Min Yang, Professor, Department of Mathematics, Statistics, and Computer Science, University of Illinois at Chicago
- Bayesian adaptive designs for dose optimization by Ying Yuan, Bettyann Asche Murray
Distinguished Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center
Upcoming events that may be of interest :
(in and around NJ)Search More Events at
